CNSPCNS Pharmaceuticals, Inc.
Health Care
Net Income (Loss) Attributable to Parent revised up 99.9% for FY 2024
This is the 2nd largest revision in CNSP's history.
Net Income (Loss) Attributable to Parent·FY 2024
Major restatement-$14.9K▲ 99.9%
was-$14.9M
Revised up.
Verify against SEC filingsShow
As reported-$14.9M
Accepted 2025-03-310001683168-25-002139
Restated-$14.9K
Accepted 2026-08-210001683168-26-006660
NetIncome · reported 3 times · point-in-time, survivorship-free. Every figure traces to its filing above.
Track this the moment it happens
Get a signal the next time CNSP — or any company on your watchlist — restates a number. Every signal lands with the diff and its source filing.